GT Biopharma, Inc.
GTBP
$0.42
-$0.01-1.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 192.32% | 130.17% | 19.63% | -45.81% | -64.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.41% | 48.68% | -6.16% | -61.26% | -37.50% |
| Operating Income | -47.41% | -48.68% | 6.16% | 61.26% | 37.50% |
| Income Before Tax | -265.08% | -510.09% | 8.71% | 61.37% | 65.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -265.08% | -510.09% | 8.71% | 61.37% | 65.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -265.08% | -510.09% | 8.71% | 61.37% | 65.75% |
| EBIT | -47.41% | -48.68% | 6.16% | 61.26% | 37.50% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 66.36% | -33.15% | 45.84% | 74.73% | 79.84% |
| Normalized Basic EPS | 87.63% | -6.15% | 48.27% | 76.15% | 53.87% |
| EPS Diluted | 66.36% | -33.15% | 45.84% | 74.73% | 79.84% |
| Normalized Diluted EPS | 87.63% | -6.15% | 48.27% | 76.15% | 53.87% |
| Average Basic Shares Outstanding | 1,191.33% | 474.85% | 76.37% | 61.90% | 69.86% |
| Average Diluted Shares Outstanding | 1,191.33% | 474.85% | 76.37% | 61.90% | 69.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |